REGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
4.3B
+19.0%
3.6B
-7.2%
3.9B
+3.5%
3.8B
+2.1%
3.7B
Cost of Revenue
576.5M
-13.9%
669.4M
+14.5%
584.6M
+12.1%
521.6M
-1.6%
530.2M
Gross Profit
3.7B
+26.5%
2.9B
-11.0%
3.3B
+2.1%
3.2B
+2.8%
3.1B
Operating Expenses
2.4B
+5.6%
2.3B
-5.6%
2.4B
+10.2%
2.2B
+6.8%
2.1B
R&D
1.8B
+6.9%
1.6B
+0.0%
1.6B
+5.6%
1.6B
+8.8%
1.4B
SG&A
662.1M
+2.2%
647.7M
-16.4%
775.0M
+17.8%
657.8M
+3.7%
634.2M
Operating Income
1.3B
+101.2%
642.9M
-26.1%
869.9M
-15.3%
1.0B
-4.9%
1.1B
EBITDA
1.4B
+85.0%
766.1M
-24.5%
1.0B
-12.8%
1.2B
-4.2%
1.2B
Net Income
1.3B
+78.3%
727.2M
-13.9%
844.6M
-42.2%
1.5B
+4.9%
1.4B
EPS (Basic)
$12.62
+80.5%
$6.99
-14.8%
$8.20
-41.8%
$14.09
+6.4%
$13.24
EPS (Diluted)
$12.23
+81.2%
$6.75
-14.1%
$7.86
-42.3%
$13.62
+6.3%
$12.81
Shares (Diluted)
106.0M
-1.6%
107.7M
+0.3%
107.4M
+0.2%
107.2M
-1.3%
108.6M
Regeneron Pharmaceuticals (REGN) โ€” Financials